Does GHK-Cu work? What published studies found

Evidence limits

Does GHK-Cu work? What do human studies show?

Where the human record comes from matters. The largest cosmetic reports named in reviews are two 2002 conference abstracts, a facial cream tested for 12 weeks in 71 women with mild-to-advanced photodamage and an eye cream tested in 41 women, and a 2026 review notes that neither was published as a full peer-reviewed paper (Najafi et al., Archives of Internal Medicine Research, 2026). That review also reports that approximately 35% of the GHK-Cu primary literature in its inclusion window includes Loren Pickart or Anna Margolina as an author and that Pickart held commercial interests in the field for decades, and it says this concentration of authorship limits the independence of the evidence base (Najafi et al., 2026).

Two further human reports sit on the record. An 8-week pilot of a GHK-Cu serum against a control serum is named in the 2026 review, and this page did not verify the primary report or its sample details, so it reports no result from that pilot (Najafi et al., 2026). In a randomised, double-blind, placebo-controlled split-face trial of 18 healthy adults aged 18 to 40, the abstract reports significantly more eyebrow hairs and wider hairs on the treated side than on the placebo side, particularly at week 12, and no serious adverse effects or allergic reactions, in a small eyebrow-only trial that does not establish scalp-hair effects or general safety (Bo et al., *Procedia of Multidisciplinary Research*, 2026). The table below sets the human studies side by side.

What does research show GHK-Cu does in the body?

GHK-Cu names the copper(II) complex of the three-amino-acid peptide glycyl-histidyl-lysine (Ufnalska et al., Inorganic Chemistry, 2021). In cultured skin fibroblasts, the cells that make connective tissue, GHK-Cu stimulated collagen synthesis independently of any change in cell number, a cell-culture result from an abstract that gives no number of cultures and does not establish a human result (Maquart et al., FEBS Letters, 1988).

Your body handles copper with care. Chemists have mapped how Cu(II) sits in GHK: three nitrogen atoms hold it, and a fourth position is taken by a labile oxygen atom from a carboxylate group in the solid form (Hureau et al., Chemistry, 2011). A 2021 laboratory chemistry study of the reaction between copper-bound GHK and glutathione suggests a transient intermediate may be a missing link in copper trafficking, the way the body hands copper between proteins, a laboratory result that does not establish a human result (Ufnalska et al., 2021).

The collagen link is old. The GHK sequence sits inside the alpha 2(I) chain of type I collagen, and Maquart and colleagues proposed in 1988 that proteases could free the tripeptide at a wound (Maquart et al., 1988). A 2018 review quotes age-associated plasma GHK values, and this page did not trace them to a primary measurement, so it reports no figure; one of the review's authors held commercial interests in the field for decades (Pickart and Margolina, 2018; Najafi et al., 2026). The GHK-Cu research guide walks through the first papers in plain English.

What have studies found about GHK-Cu and wound healing?

In 24 rats with ischaemic (poorly supplied) skin wounds, wound area was significantly smaller with a tripeptide-copper gel than with no treatment on several days, the gel differed from its vehicle gel only on days 3 and 9, and by day 13 the initial wound area had decreased by 64.5% with the gel, 45.6% with the vehicle gel and 28.2% with no treatment, a rat result that does not establish a human effect (Canapp et al., Veterinary Surgery, 2003). In a trial of 86 evaluable people with venous stasis ulcers, a tripeptide-copper cream did not differ from an inert cream, while silver sulfadiazine cream reduced ulcer size against both, in a trial whose abstract does not state its length (Bishop et al., Journal of Vascular Surgery, 1992).

Not every animal result agrees. In irradiated rat skin flaps (13 treated and 10 control animals), GHK-Cu gel showed no difference in flap ischaemia, blood-vessel number or area, or VEGF staining compared with controls, a rat result that does not establish a human result (Parker et al., Otolaryngology–Head and Neck Surgery, 2013). In 72 rats after knee-ligament reconstruction, the GHK-Cu groups had a smaller side-to-side difference in knee laxity than the saline group at 6 weeks, with no significant difference at 12 weeks, and the authors wrote that the beneficial effects could not last as treatment was discontinued, a rat result that does not establish a human result (Fu et al., Journal of Orthopaedic Research, 2015).

In rat wound chambers, GHK-Cu raised collagen and glycosaminoglycan content in a concentration-dependent way and a control tripeptide had no significant effect, a rat result from an abstract that gives no number of rats and does not establish a human result (Maquart et al., Journal of Clinical Investigation, 1993). A registered human trial has no results yet: NCT07437586 is a Phase 2 study of GHK-Cu in small standardised wounds in healthy adults, and ClinicalTrials.gov listed it as recruiting, with status last verified in February 2026 and no results posted, on 14 October 2026.

What have studies found about GHK-Cu, skin collagen and wrinkles?

In cultured skin fibroblasts, GHK-Cu stimulated collagen synthesis, a cell-culture result whose abstract gives no culture count and that does not establish a human result (Maquart et al., FEBS Letters, 1988). An 8-week pilot of a GHK-Cu serum against a control serum is named in a 2026 review, and this page did not verify the primary report or its sample details, so it reports no result from that pilot (Najafi et al., Archives of Internal Medicine Research, 2026). In the randomised laser-resurfacing trial, 13 people completed follow-up, the groups did not differ on objective measures, and the GHK-Cu group rated its skin quality higher on a questionnaire, in a small post-laser aftercare trial that does not establish an effect for other skin settings (Miller et al., Archives of Facial Plastic Surgery, 2006).

A 2018 review also describes a 12-week thigh-skin study from a 1998 pilot that this page did not open, so it reports no result from that pilot (Pickart and Margolina, 2018).

Skin-permeation work adds a limit. In flow-through diffusion cells, copper from a copper-tripeptide solution crossed human skin samples and some was retained in the skin, a laboratory result whose abstract gives no skin-sample count, measures copper rather than intact peptide and does not establish a human result (Hostynek et al., Inflammation Research, 2011). A 2025 review in BioImpacts found 'a surprising absence of clinical studies' of GHK-Cu and a palmitoylated GHK derivative as anti-wrinkle ingredients (Mortazavi et al., 2025).

Have studies measured skin glow with GHK-Cu?

None of the study abstracts opened for this page names skin glow as a measured outcome. Human studies of GHK-Cu measured wrinkles, skin density and thickness, laxity, redness and, in one review's wording, clarity (Pickart and Margolina, 2018; Miller et al., 2006). Glow is a visual impression, and none of the trial abstracts opened defines it as a measurement. The word also appears as a product name for blends, which is a separate question from what GHK-Cu itself does; the GHK-Cu and Glow page covers that.

What have studies found about GHK-Cu and hair growth?

The sources searched for this page did not include a controlled human study of GHK-Cu alone on scalp hair, and the evidence is small. A 2007 laboratory study found that AHK-Cu, a related copper peptide, stimulated the elongation of human hair follicles kept in culture and the proliferation of cultured dermal papilla cells, the cells at the base of a follicle, a culture result whose abstract gives no donor or culture counts and that does not establish a human result (Pyo et al., Archives of Pharmacal Research, 2007). A 2026 split-face trial in 18 healthy adults reported significantly more eyebrow hairs on the side treated with a GHK-Cu serum than on the placebo side, particularly at week 12, in a small trial on eyebrows and not scalp hair (Bo et al., *Procedia of Multidisciplinary Research*, 2026).

The human hair reports cover several formulations. In a 6-month randomised, placebo-controlled trial of 45 men with pattern hair loss, total hair count rose by 52.6 and 71.5 in the two groups given a complex of 5-aminolevulinic acid and GHK peptide and by 9.6 with placebo, the ratio of change differed significantly from placebo in one group, hair length and thickness did not differ among the groups and no adverse event occurred in the three groups, in a trial whose abstract names no copper (Lee et al., Annals of Dermatology, 2016). In a single-arm study of 1000 people given a six-ingredient hair formulation that included copper tripeptide-1, hair-pull testing showed significantly less hair fall in 83% and total hair count was significantly higher at 1 year (P = 0.002), with no control group and six ingredients, so no single ingredient can be credited (Kapoor and Shome, Journal of Cosmetic and Laser Therapy, 2018).

The related-peptide question has its own limit. A 2026 Pharmaceutics review describes the AHK-Cu evidence base as thin and poorly characterised (Mateescu et al., 2026), and the sources searched for this page did not include a study that compared AHK-Cu with GHK-Cu.

What have studies found about GHK-Cu and body weight?

The search did not identify a trial of GHK-Cu for weight reduction in healthy people; a 2025 mouse colitis study measured disease-related weight loss, which is a different question and a mouse result whose abstract gives no group sizes and that does not establish a human result (Mao et al., 2025). A PubMed search on 14 October 2026 combined GHK, GHK-Cu, copper peptide and copper tripeptide with the terms obesity, adipose tissue, body weight and weight loss; the records reviewed did not include a trial of weight reduction in healthy people. A 2026 review in Sports Medicine covers GHK-Cu among other peptides and describes rigorous human safety data for many unapproved peptides as scarce (Mendias and Awan, 2026).

One mouse study mentions weight, but as a disease marker. In a 2025 mouse model of colitis, the abstract reports that GHK-Cu alleviated the weight loss that the colitis caused, a disease-model finding whose abstract gives no group sizes and that does not establish a human result or weight reduction in healthy animals (Mao et al., Frontiers in Pharmacology, 2025).

Does GHK-Cu affect sleep or cause sleepiness?

The sources searched for this page did not include a human study that tested GHK-Cu on sleep or reported sleepiness as an effect. A PubMed search on 14 October 2026 combining GHK, GHK-Cu, copper peptide and copper tripeptide with sleep, sleepiness or drowsiness returned 10 records, and the one that concerned GHK and sleep was a mouse study. In that study of GHK, the peptide without copper, sleep-deprived aging mice treated with GHK did not show the acute learning impairment seen in sleep-deprived mice treated with saline, and GHK prevented a rise in two inflammation-linked markers, MCP-1 and nitrotyrosine, in the hippocampus, a memory region; it is a mouse result that measured memory after lost sleep rather than sleep duration, from an abstract that gives no group sizes and does not establish a human result (Rosenfeld et al., Aging Pathobiology and Therapeutics, 2023).

The human trial abstracts opened for this page describe adverse events in general terms. In 18 healthy adults in a small split-face eyebrow trial, the abstract reports no serious adverse effects or allergic reactions, which does not establish general safety (Bo et al., 2026). In 45 men with pattern hair loss given a multi-ingredient formulation that names GHK and no copper, the abstract reports no adverse event in any group, which does not establish the safety of GHK-Cu (Lee et al., 2016). Neither abstract lists drowsiness. An abstract is a summary, so a symptom missing from it is not proof that it never happened.

Has GHK-Cu caused itching or skin reactions in studies?

In cultured keratinocytes (skin cells), GHK-Cu was not cytotoxic and did not significantly change irritation-related markers, whereas copper chloride and copper acetate raised IL-1α, IL-8, HSPA1A and FOSL1, a cell-culture assay whose abstract gives no culture count and that does not establish a human result or an itch rate (Li et al., Scientific Reports, 2016). Among 18,918 men on a multi-drug regimen that included a copper tripeptide, 802 (4.2%) had minor complications, including itching and erythema of the scalp, and the regimen's other drugs mean the itching cannot be assigned to the copper tripeptide (Tanaka et al., *Journal of Clinical and Aesthetic Dermatology*, 2018).

The regimen contained other medicines and ingredients, so it cannot isolate the copper tripeptide's adverse effects (Tanaka et al., 2018). The cell study covers one cell type in a dish and does not establish a human result. Neither result is a measured itch rate for GHK-Cu alone.

How fast did results appear in GHK-Cu studies?

Studies report results at fixed check-in points, not at a time when results begin. The rat wound study traced wounds daily for 13 days (Canapp et al., 2003). The human studies above ran 8 weeks for the wrinkle trial and 12 weeks for the laser-resurfacing and eyebrow trials (Najafi et al., 2026; Miller et al., 2006; Bo et al., 2026). No trial abstract opened for this page reports how soon a person first showed a change, so the abstracts opened give no answer to how fast it works.

The planned wound trial keeps the same pattern. The registry entry for NCT07437586 says wounds will be photographed over 3 weeks and a follow-up visit will assess scar quality (ClinicalTrials.gov, checked 14 October 2026).

Do GHK-Cu effects last or become permanent?

The sources read for this page do not show permanent effects of GHK-Cu, and the longest follow-up of a controlled study of GHK-Cu itself that was opened was 12 weeks (Miller et al., 2006; Bo et al., 2026). In 72 rats after knee-ligament reconstruction, the GHK-Cu groups had a smaller side-to-side difference in knee laxity at 6 weeks, with no significant difference at 12 weeks, and the authors wrote that the beneficial effects could not last as treatment was discontinued, a rat result that does not establish a human result (Fu et al., Journal of Orthopaedic Research, 2015). In 1,000 people, a single-arm study of a six-ingredient hair formulation reported a significantly higher total hair count at 1 year, but it had no control group and several ingredients (Kapoor and Shome, 2018).

What forms of GHK-Cu did studies use, and did any study compare them?

Studies tested GHK-Cu in cream, gel, serum and liposome formulations, and the sources read for this page include no human study that compared forms head to head. Laboratory studies compare how far the peptide travels into skin instead. In a diffusion cell, copper from a GHK tripeptide solution crossed human skin samples, a laboratory result whose abstract gives no skin-sample count, measures copper rather than intact peptide and does not establish a human result (Hostynek et al., 2011). A 2025 review found limited clinical evidence on GHK-Cu skin delivery (Mortazavi et al., BioImpacts, 2025).

The form matters for another reason. A 2026 review argues that the label 'GHK-Cu' does not fix the chemical state, because the metal-to-ligand ratio, the pH and the free-copper content are often not fully reported (Mateescu et al., 2026). It separates free GHK, canonical GHK-Cu and GHK-derived copper peptides, and asks that evidence from each be kept separate.

How do researchers tell whether GHK-Cu worked in a study?

Researchers decide with set measurements taken before and after and compared against a control group, and controlled studies distinguish objective measurements from prespecified patient-reported outcomes. The studies above measured wound area on traced outlines (Canapp et al., 2003), redness by computer analysis and blinded evaluators (Miller et al., 2006), hair count and hair diameter from standardised photographs (Bo et al., 2026) and collagen content in tissue (Maquart et al., 1993). In 13 people who completed a small post-laser aftercare trial, which does not establish an effect for other skin settings, the GHK-Cu group rated its skin quality higher (P = 0.04) while objective evaluation found no significant between-group difference in improvement in wrinkles or skin quality (Miller et al., 2006).

What do studies show about KPV and GHK-Cu together?

The sources searched for this page did not include a study that tested KPV and GHK-Cu together. KPV (lysine-proline-valine) is the last three amino acids of alpha-MSH, a 13-amino-acid hormone made in the body (Brzoska et al., Endocrine Reviews, 2008). In mice with chemically induced colitis, KPV led to earlier recovery and a stronger regain of body weight and reduced inflammatory infiltrates, a mouse result from an abstract that gives no group sizes and does not establish a human result (Kannengiesser et al., Inflammatory Bowel Diseases, 2008). GHK-Cu was tested in a separate mouse colitis model and, per the abstract, attenuated inflammatory damage and suppressed inflammatory cytokines, also a mouse result whose abstract gives no group sizes and that does not establish a human result (Mao et al., 2025). A 2025 review covers both tripeptides in wound healing, one after the other and not as a mixture (Adnan et al., International Journal of Medical Sciences, 2025).

Is research-use GHK-Cu the same material the studies tested?

No. The studies above examined specific formulations under trial conditions; their results are tied to the material described in each report. Research-use reference material is a laboratory compound. It is not a medicine, is not a substitute for one, and is not for human or animal use. The published results describe what happened in those studies and say nothing about any other material.

The catalogue lists GHK-Cu reference material as freeze-dried laboratory stock. The sample report on file is a third-party heavy-metals screen, which does not measure purity or confirm identity, and matching current certification is unverified. The quality and verification hub explains what each laboratory document records and what it cannot show.